TrialSignal
Clinical trial intelligence report
A Phase 2b, Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study of 2 Dose Levels of VX 787 Administered as Monotherapy and One Dose Level of VX-787 Administered in Combination With Oseltamivir for the Treatment of Acute Uncomplicated Seasonal Influenza A in Adult Subjects
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT02342249
Status
COMPLETED
Phase
PHASE2
Sponsor
Janssen Research & Development, LLC
Executive brief
Investment-Ready Snapshot
The purpose of this study is to evaluate the antiviral effect, as measured by viral titer in nasal secretions in adults with acute uncomplicated seasonal influenza A following administration of VX-787.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT02342249
Indication
Influenza A
Modality
small molecule
Target
VX-787 300 mg, VX-787 600 mg, Oseltamivir 75 mg, Placebo
Intervention
VX-787 300 mg, VX-787 600 mg, Oseltamivir 75 mg, Placebo
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.